SANTA ANA, Calif., Nov. 8, 2000 (PRIMEZONE) -- The following is being issued by Donner Corp. International, a Santa Ana, California-based investment banking and institutional research firm and a member of the National Association of Securities Dealers, CRD number 37702.
Donner Corp. International today reiterated its Speculative Buy Recommendation on Advanced Biotherapy, Inc. because the Company has made substantial progress in moving its programs forward, specifically in the area of its proprietary treatment for rheumatoid arthritis and multiple sclerosis. Advanced Biotherapy Concepts, Inc. (OTCBB:ADVB), Woodland Hills, Calif., is a biotechnology company engaged in the development of treatments for severe autoimmune diseases, most notably multiple sclerosis (MS) and rheumatoid arthritis (RA).
Based on its newly released clinical data, Donner believes that the Advanced Biotherapy drug, when and if developed, could have comparable sales to that of Biogen, Inc.'s Avonex(r) (Nasdaq:BGEN) and Immunex Corp.'s Enbrel(r) (Nasdaq:IMNX), which generated $620 million in sales and $367 million in sales, respectively, in 1999.
A Donner report was issued prior to this press release. For copies of the report, please visit the Donner Corp. International website at www.donnercorp.com.
Any information or opinion provided in this report/release does not solicit or make an offer to buy or sell any securities or any options, futures or other derivatives related to such securities herein. DCI and its affiliates may trade for their own accounts in any securities of the issuer or in related securities. DCI or its affiliates, directors, officers and employees, may have a long or short position in securities of the issuer or related investments. DCI or its affiliates may from time to time perform investment banking or other services for, or solicit investment banking or other business from, any entity mentioned in this report/release. This research report/release has been prepared for general circulation and is circulated for general information only. It does not have regard to the specific investment objective, financial situation, suitability, and the particular need of any specific person who may receive this report/release. Investors should seek financial advice regarding the appropriateness of investing in any securities or investment strategies discussed or recommended in this report/release and should understand that statements regarding future prospects may not be realized. Investors should note that income from such securities, if any, may fluctuate and that each security's price or value may rise or fall substantially. Accordingly, investors may receive back less than originally invested. Past performance is not indicative of future performance. Copyright 2000 DCI. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that DCI was recently compensated by ADVB in the form of a $2,500 due diligence fee, and DCI receives $5,000 per month for services provided. DCI also receives $3.00 for each prospective investor name delivered to ADVB. DCI will receive 20,000 warrants to purchase shares of restricted common stock in ADVB at $0.50 per share. DCI may receive compensation for DCI databases, and DCI may receive additional stock, options, or warrants to purchase stock of ADVB, which have not been determined as of the date of this report/release. There will be a negotiable fee for merger, acquisition, institutional transactions or other business relationships entered between ADVB and companies introduced by DCI; the fee for any and all transactions involving this provision will be negotiated prior to such introduction. This document shall not be copied or reproduced in any form without the expressed written and authorized consent of Donner Corp. International.